Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of durvalumab added to neoadjuvant nab-paclitaxel followed by epirubicin/cyclophosphamide in triple-negative breast cancer
2015-002714-72Phase 2Completed
- Sponsor
- GBG Forschungs
- Start
- Oct 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab and paclitaxel in triple-negative breast cancer (TNBC) and breast cancer (2 arms), sponsored by GBG Forschungs. Started Oct 2015; status: completed.
02
Drugs
durvalumabpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2015-002714-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002714-72.